Bioadaptives, Inc. (BDPT) Liabilities and Shareholders Equity (2013 - 2026)

Bioadaptives has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $135949.0 in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 23.09% year-over-year to $135949.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $758725.0 (up 77.5% YoY) and the FY2025 annual result came in at $225901.0, down 13.74% from the prior year.
• Liabilities and Shareholders Equity fell to $135949.0 in Q1 2026 per BDPT's latest filing, from $225901.0 in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $329302.0 in Q3 2023 and troughed at $8735.0 in Q2 2024.
• A 5-year average of $115461.4 and a median of $87072.0 in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 85.91% in 2024, then surged 3019.81% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $37314.0 in 2022, then soared by 178.71% to $103998.0 in 2023, then soared by 151.82% to $261885.0 in 2024, then fell by 13.74% to $225901.0 in 2025, then slumped by 39.82% to $135949.0 in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $135949.0, $225901.0, and $124360.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.